Novartis AG said the final analysis of a study of its Lutathera radioligand therapy for the treatment of cancer showed clinically relevant improvement in median overall survival data.
A secondary objective of the Phase 3 study of treatment using Lutathera in patients with midgut neuroendocrine tumors showed prolongation in median overall survival of 11.7 months, the Swiss drugmaker said late Thursday.
This analysis, however, didn't reach statistical significance, Novartis said. The analyses of overall survival may have been affected by multiple factors, the company said. No new safety concerns emerged in the study analysis, it said.
The study's previously reported primary analysis showed statistically significant improvement in progression-free survival, the company said.
Radioligand therapy combines a targeting compound that binds to receptors expressed by tumors and a radioactive isotope, causing DNA damage that inhibits tumor growth and replication and may lead to cell death, the company said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.